Malnutrition and Sarcopenia Among Primary Ciliary Dyskinesia
ConditionPrimary Ciliary Dyskinesia (PCD)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age6-18
SponsorIzmir Democracy University
About this trial
The prevalence and causes of malnutrition and sarcopenia in children and adolescents with Primary ciliary dyskinesia (PCD) have not been sufficiently elucidated. The aim of this study is to investigate the prevalence of malnutrition and sarcopenia in children and adolescents with PCD.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Unexplained neonatal respiratory distress, lateralization defect, productive cough, bronchiectasis, daily nasal congestion, and pansinusitis, as well as laboratory tests such as high-speed video microscopy, transmission electron microscopy, or genetic testing according to the European Respiratory Society diagnostic guidelines.
Cooperative individuals,
Individuals who have never smoked
Willingness to participate in the study
Disqualifiers
Individuals with any acute, chronic, or systemic illness other than PCD
Individuals who smoke or are quitting smoking
Individuals who are not willing to participate in the study
Individuals who are uncooperative
Trial population
The study will include children and adolescents aged 6-18 years with Primary Ciliary Dyskinesia (PCD).
Trial design
Design model
Case-only
Time perspective
Cross-sectional
Treatments tested in this trial
Physical assessments of individuals
Other interventionParticipants will be evaluated in terms of nutritional status, anthropometric measurements (waist circumference, hip circumference, waist-to-height ratio, skinfold measurements) and body composition, pulmonary functions, anaerobic capacity, muscle strength.
Treatment groups
15 Participants
are divided into 1 treatment groupGroup A: Patient of Primary Ciliary Dyskinesia1 intervention
Trial outcomes
Primary outcomes
1
Handgrip Muscle Strength in Participants
Bilateral grip strength in children and adolescents with PCD will be measured in kgF using a hand dynamometer.
Time frame
From enrollment to the end of treatment at 1 yearSecondary outcomes
1
Malnutrition risk score in Participants
The Nutritional Status and Growth Risk Screening Tool will be used to assess the risk of growth failure. The total score on this scale ranges from 0 to 5; a score of 0 indicates a low risk of malnutrition, a score of 1-3 indicates a moderate risk of malnutrition, and a score of 4-5 indicates a high risk of malnutrition.
Time frame
From enrollment to the end of treatment at 1 year2
Body Weight
Body weight in children and adolescents with PCD will be measured using a pediatric scale.
Time frame
From enrollment to the end of treatment at 1 year3
Height
In children and adolescents with PCD, height will be measured using a stadiometer.
Time frame
From enrollment to the end of treatment at 1 year4
Body Mass Index
For children and adolescents with PCD, the body mass index will be calculated by dividing body weight by the square of height in meters.
Time frame
From enrollment to the end of treatment at 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: